Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (137)	12/5/2002 2:46:13 PM
From: Jibacoa	Respond to of 3722

ONXX It had an intra-day double top (at 1.00-1.01PM <g>) at the 7.84 level, but it seems it may be able to close above its December 2 H of 7.40 (It is trading at present at 7.44) Besides the appointment of Dr.Grillo-Lopez to the Board a few weeks ago, what could be making the shares move is the reported results of its BAY 43-9006, which is an oral, cancer drug that appears to work by blocking the enzyme raf kinase. The company said a few weeks ago that 27 of 114 patients, given higher doses of BAY 43-9006 as a stand alone treatment, haven't had their cancers progress after more than six months and seven of these patients treated for more than a year, had no evidence of advancement of their cancers.(In that study were included patients with a variety of advanced stage cancer, including colon, liver, breast and ovarian.) BAY 43-9006 supposedly acts "downstream" from other new cancer drugs like AZN's Iressa which targets the "epidermal growth factor receptor" and IMCL's Erbitux. At any rate, the stock is up 20.78% and the volume is now above 266K bigcharts.marketwatch.com Bernard